Announcement PDF ASX Announcement/Press Release | 21 August 2025 AdAlta Limited (ASX:1AD) TechKnow Invest Conference presentation recording AdAlta Limited (ASX:1AD) (“AdAlta” or “the Company”), developer of next generation cell and protein therapeutic products advises that a recording of CEO and Managing Director, Dr Tim Oldham’s presentation at the TechKnow Invest Roadshow on 19 August 2025 is now available on the Company’s website. The presentation highlights the two global trends powering AdAlta’s “East to West” strategy: 1. The CAR-T cell therapy revolution: technology enabling the engineering of a patient's own immune cells to fight cancer, creating a living drug where a single dose is potentially a cure 2. The rise of China biotech: creating a now globally respected pool of innovation, particularly in CAR-T cell therapy The presentation also describes the business system AdAlta is adopting and how successfully deploying it will create value for shareholders. AdAlta will license highly differentiated, clinical stage products at low cost from China ("East"), develop them cost effectively in Australia and then on-license to realise significant value creation in "Western" markets. To view the recording and to engage in discussion, visit AdAlta’s InvestorHub here: https://investorhub.adalta.com.au/link/PwbB2r This ASX announcement has been authorised for release by the CEO of AdAlta Limited (ASX:1AD). For further information, please contact: AdAlta Limited (ASX:1AD) Tim Oldham CEO & Managing Director P: +61 3 9479 5159 E: t.oldham@adalta.com.au About AdAlta AdAlta (ASX: 1AD) is a clinical stage biotechnology business addressing the need for effective cellular immunotherapies for the treatment of solid cancers. Through its ‘East to West’ strategy, the Company is integrating Asia's prowess in T cell therapy development with the efficiency and quality of Australia's clinical and manufacturing ecosystem to create a pathway connecting ‘Eastern’ innovation in cellular immunotherapies with ‘Western’ regulated markets and patients. AdAlta in-licenses products from Asian originators and invests to establish US FDA regulated manufacturing and conduct Phase I clinical studies with potential to position each product for on-licensing to larger biopharmaceutical companies for potential registrational studies and commercialization. AdAlta implements a disciplined approach to asset selection focused on highly differentiated T cell therapy products supported by clinical data in solid cancers. The company adopts a capital efficient business model AdAlta Limited (ASX:1AD) · ABN: 92 120 332 925 · www.adalta.com.au Suite 201, 697 Burke Road, Camberwell VIC 3124 Australia 1 delivering a rapid return on investment in each project that is replicable and provides opportunities to scale across multiple products. Solid tumours account for 90% of cancers yet remain underserved by current cellular immunotherapies. AdAlta aims to dominate this high-growth segment. The cellular immunotherapy market is projected to grow at a compound annual growth rate of 34% to reach US$20.3 billion by 2028. AdAlta’s first in class fusion protein, AD-214, takes a whole new approach to fibrotic diseases of the lung and kidney, such as the degenerative and fatal Idiopathic Pulmonary Fibrosis. Following demonstration of efficacy in multiple animal models of disease and two successful Phase I clinical studies, AD-214 is available for partnering. To learn more, please visit: www.adalta.com.au For more information Join our InvestorHub Follow us on LinkedIn Follow us on X (formerly Twitter) 2